Atara Biotherapeutics, Inc.
ATRA
Rank in Stocks
#20577
Founded in 2012 and headquartered in South San Francisco, California, Atara... Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral infections. A key therapeutic candidate, tabelecleucel, is currently undergoing Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease, as well as various hematologic and solid tumors, such as nasopharyngeal carcinoma. The company is also advancing a robust pipeline of next-generation CAR T immunotherapies designed to combat hematologic malignancies and solid tumors. This includes ATA2271 and ATA3271 targeting mesothelin, alongside ATA2431 and ATA3219 for B-cell malignancies. Furthermore, Atara is developing ATA188 for the treatment of multiple sclerosis and the ATA368 program specifically for cancers associated with human papillomavirus (HPV). To bolster its research and development efforts, Atara Biotherapeutics has established significant collaborations and licensing agreements. These include a licensing partnership with Memorial Sloan Kettering Cancer Center, a license and R&D collaboration with QIMR Berghofer Medical Research Institute, and a strategic alliance with H. Lee Moffitt Cancer Center. Additionally, the company holds a strategic partnership with Bayer AG focused on mesothelin-targeted CAR T-cell therapies for solid tumors.
Share Price
$8.18
Last synced: 2026-11-09
Market Cap
$82.11M
Change (1 day)
3.94%
Change (1 year)
-34.87%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Atara Biotherapeutics, Inc. (ATRA)
Category
Healthcare
EPS for Atara Biotherapeutics, Inc. (ATRA)
EPS as of June 2026 TTM: $-1.18
According to Atara Biotherapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-1.18. At the end of 2025 the company had an EPS of $2.61, an increase over its 2024 EPS of $-11.41.
EPS history for Atara Biotherapeutics, Inc. from 2012 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.18 | -145.21% |
| 2025 | $2.61 | -122.87% |
| 2024 | $-11.41 | -82.49% |
| 2023 | $-65.18 | 16.48% |
| 2022 | $-55.96 | -38.36% |
| 2021 | $-90.78 | -12.40% |
| 2020 | $-103.63 | -26.91% |
| 2019 | $-141.78 | 7.70% |
| 2018 | $-131.64 | 31.60% |
| 2017 | $-100.03 | 45.43% |
| 2016 | $-68.78 | 23.00% |
| 2015 | $-55.92 | -60.18% |
| 2014 | $-140.42 | -38.17% |
| 2013 | $-227.09 | 1,250.92% |
| 2012 | $-16.81 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,427.12% |
US
|
|
| $-7.07 | 499.15% |
US
|
|
| $-5.29 | 348.31% |
AU
|
|
| $12.88 | -1,191.53% |
BE
|
|
| $21.56 | -1,927.12% |
NL
|
Questions about Atara Biotherapeutics, Inc.'s earnings per share (EPS)
What is Atara Biotherapeutics, Inc.'s earnings per share (EPS)?
Atara Biotherapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-1.18, as of Jun 2026.
What was Atara Biotherapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Atara Biotherapeutics, Inc.'s earnings per share (EPS) was $2.61, compared with $-11.41 in 2024.
How has Atara Biotherapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Atara Biotherapeutics, Inc.'s earnings per share (EPS) was highest in 2025 ($2.61) and lowest in 2020 ($-103.63).
How does Atara Biotherapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Atara Biotherapeutics, Inc.'s earnings per share (EPS) ($-1.18) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.